SomaLogic (SomaLogic) Interest Expense : $0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SomaLogic Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. SomaLogic's interest expense for the three months ended in Sep. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. SomaLogic's Operating Income for the three months ended in Sep. 2023 was $ -23.93 Mil. SomaLogic's Interest Expense for the three months ended in Sep. 2023 was $ 0.00 Mil. GuruFocus does not calculate SomaLogic's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

SomaLogic Interest Expense Historical Data

The historical data trend for SomaLogic's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomaLogic Interest Expense Chart

SomaLogic Annual Data

Trend

Dec20

Dec21

Dec22

Interest Expense

-18.34

-1.32

SomaLogic Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Expense	Get a 7-Day Free Trial								-	-	-	-	-

SomaLogic Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

SomaLogic (NAS:SLGC) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

SomaLogic's Interest Expense for the three months ended in Sep. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2023 was $-23.93 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was $2.76 Mil.

SomaLogic's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

GuruFocus does not calculate SomaLogic's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. SomaLogic Inc has enough cash to cover all of its debt. Its financial situation is stable.

SomaLogic (SomaLogic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (NAS:SLGC) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2945 Wilderness Place, Boulder, CO, USA, 80301

Website

https://www.somalogic.com

SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.

Executives

Alison Marie Roelke	officer: Chief People Officer	900 INNOVATORS WAY, SIMI VALLEY CA 93065
Adam Taich	officer: Interim CEO	C/O SOMALOGIC, INC., 2945 WILDERNESS PLACE, BOULDER CO 80301
Ruben Gutierrez	officer: General Counsel	6435 AVENIDA WILFREDO, LA JOLLA CA 92037
Kathy L Hibbs	director	C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
Jason Ryan	director	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas D. Carey	director	8 PAIGE STREET, HINGHAM MA 02043
Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Tycho Peterson	director	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Eli Casdin	director	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Shaun M. Blakeman	officer: Chief Financial Officer	C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Anne H. Margulies	director	C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Richard A Post	director	998 LACOSTA LANE, LANE TREE CO 80124
Charles M. Lillis	director	13 CASTLE PINES DRIVE N, CASTLE ROCK CO 80108
Stephen Quake	director	C/O FLUIDIGM CORPORATION, 7000 SHORELINE COURT, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Robert Barchi	director